Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo.
Saved in:
| Title: | Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. |
|---|---|
| Authors: | Su X; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Luo R; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Ruan S; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Zhong Q; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Zhuang Z; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Xiao Z; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Zhang P; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Cheng B; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China., Gong T; Central Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Electronic address: derma123@126.com., Ji C; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Electronic address: jichaofy@fjmu.edu.cn. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Dec; Vol. 89 (6), pp. 1257-1259. Date of Electronic Publication: 2023 Jul 28. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
